The effect of combining therapeutic drug monitoring of antihypertensive drugs with personalised feedback on adherence and resistant hypertension: the (RHYME-RCT) trial protocol of a multi-centre randomised controlled trial

[1] Vongpatanasin W(2014)Resistant hypertension: A review of diagnosis and management JAMA 311 2216-2224

[2] Mancia G(2013)2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) J Hypertens 31 1281-1357

[3] Fagard R(2001)High prevalence of cardiac and extracardiac target organ damage in refractory hypertension J Hypertens 19 2063-2070

[4] Narkiewicz K(2014)Hospital admissions for hypertensive crisis in the emergency departments: a large multicenter Italian study PLoS ONE 9 e93542-1109

[5] Redon J(2014)Medication non-adherence as a critical factor in the management of presumed resistant hypertension: a narrative review EuroInterven: J EuroPCR Collab Work Group Interven Cardiol Eur Soc Cardiol 9 1102-72

[6] Zanchetti A(2015)Assessment of adherence to treatment in patients with resistant hypertension using toxicological serum analysis. A subgroup evaluation of the RESIST-POL study Pol Arch Med Wewn. 125 65-774

[7] Bohm M(2013)Resistant hypertension? Assessment of adherence by toxicological urine analysis J Hypertens 31 766-191

[8] Cuspidi C(2009)Intensive monitoring of adherence to treatment helps to identify "true" resistant hypertension J Clin Hypertens 11 183-257

[9] Macca G(2017)Detecting non-adherence by urine analysis in patients with uncontrolled hypertension: rates, reasons and reactions J Hum Hypertens 31 253-861

[10] Sampieri L(2014)High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS/MS) urine analysis Heart 100 855-306

[1] Vongpatanasin W(2014)Resistant hypertension: A review of diagnosis and management JAMA 311 2216-2224

[2] Mancia G(2013)2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) J Hypertens 31 1281-1357

[3] Fagard R(2001)High prevalence of cardiac and extracardiac target organ damage in refractory hypertension J Hypertens 19 2063-2070

[4] Narkiewicz K(2014)Hospital admissions for hypertensive crisis in the emergency departments: a large multicenter Italian study PLoS ONE 9 e93542-1109

[5] Redon J(2014)Medication non-adherence as a critical factor in the management of presumed resistant hypertension: a narrative review EuroInterven: J EuroPCR Collab Work Group Interven Cardiol Eur Soc Cardiol 9 1102-72

[6] Zanchetti A(2015)Assessment of adherence to treatment in patients with resistant hypertension using toxicological serum analysis. A subgroup evaluation of the RESIST-POL study Pol Arch Med Wewn. 125 65-774

[7] Bohm M(2013)Resistant hypertension? Assessment of adherence by toxicological urine analysis J Hypertens 31 766-191

[8] Cuspidi C(2009)Intensive monitoring of adherence to treatment helps to identify "true" resistant hypertension J Clin Hypertens 11 183-257

[9] Macca G(2017)Detecting non-adherence by urine analysis in patients with uncontrolled hypertension: rates, reasons and reactions J Hum Hypertens 31 253-861

[10] Sampieri L(2014)High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS/MS) urine analysis Heart 100 855-306